SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 936-943. Prepublished online as a Blood First Edition Paper on September 28, 2006; DOI 10.1182/blood-2006-07-035915. This Article Full Text (PDF) All Versions of this Article: blood-2006-07-035915v1 109/3/936    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lehrnbecher, T. Articles by Creutzig, U. Search for Related Content PubMed PubMed Citation Articles by Lehrnbecher, T. Articles by Creutzig, U. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 17, 2006 Accepted September 8, 2006 Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia Thomas Lehrnbecher*, Martin Zimmermann, Dirk Reinhardt, Michael Dworzak, Jan Stary, and Ursula Creutzig Pediatric Hematology and Oncology, University of Frankfurt, Frankfurt, Germany Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany St. Anna Kinderspital, Vienna, Austria 2nd Medical Faculty, Charles University, Prague, Czech Republic Pediatric Hematology and Oncology, University of Munster, Munster, Germany * Corresponding author; email: thomas_lehrnbecher{at}yahoo.com. Children with acute myelogenous leukemia (AML) have a high risk of infectious complications which might be reduced by prophylactic granulocyte colony-stimulating factor (G-CSF). However, G-CSF could induce AML blast proliferation. The prospective randomized trial AML-BFM 98 investigated the impact of G-CSF on hematopoetic recovery and infectious complications (primary endpoints) and on outcome (secondary endpoint) in children (0-18 years) with de novo AML. Patients with >5% blasts in day 15 bone marrow or with FAB M3 were not included. Between 1998 and 2003, 161 children with AML were randomized to receive G-CSF after induction 1 and 2, whereas 156 patients were assigned to the control group. Time of neutropenia after induction 1 and 2 was significantly shorter in the G-CSF group (23 vs 18 and 16 vs 11 days, P=.02 and .001, respectively). G-CSF did not decrease the incidence of febrile neutropenia (72/36 vs 78/37), microbiologically-documented infections (27/25 vs 36/19) and infection-associated mortality (5 vs 2). Both groups had similar 5-year-EFS (59± 4% vs 58± 4%). Since G-CSF does not influence the risk of infectious complications or outcome in children undergoing therapy for AML, one can not advocate the routine use of G-CSF in this patient group. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020